The demand for antibacterial cleaning supplies continues to climb in response to the COVID-19 pandemic, and healthcare institutions are looking for effective alternatives to traditional solutions.
To fill this need, Contec, Inc. is scaling up production of its Sporicidin brand disinfectant, most often used for mold and water damage remediation, and turned to Milliken & Company to help produce mass quantities.
“Milliken immediately came to mind when we decided to bring on a new manufacturing partner,” shared Jack McBride, Contec, Inc. CEO. “Milliken is a trusted, key community player with the mass production, quality systems and speed-to-market capabilities needed to help us provide critical cleaning solutions to healthcare facilities without delay.”
The EPA-registered intermediate level disinfectant cleans, disinfects and deodorizes, and it provides 100 per cent kill of pathogenic vegetative organisms, including MRSA, VRE and Avian Influenza A Virus (H9N2 and H1N1) with continuous residual activity for up to six months. Compatible with plastics, wood, glass and metals, alcohol-free Sporicidin brand disinfectant is non-staining, non-abrasive and non-corrosive. Notably, the disinfectant carries a Category IV EPA toxicity rating ⎯ the lowest toxicity rating given to antimicrobials.
Sporicidin production at Milliken began on May 12, after a record ramp-up of only four weeks. Typical similar partnerships require three to six months to arrange.
“Companies are adapting their core competencies to meet the global challenges brought on by COVID-19,” said Halsey M. Cook, president and CEO of Milliken & Company. “Partnering with Contec, Inc. was a natural fit, and gave Milliken the opportunity to quickly reconfigure our manufacturing capabilities and rapidly solve problems for our customers and communities.”
Print this page
